Navigation Links
S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
Date:11/27/2007

SINGAPORE, Nov. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the expansion of its proprietary pipeline, with its third development candidate, SB1317. This is a novel orally-available small molecule compound targeted for the treatment of acute leukemias.

SB1317 is designed to selectively inhibit major signalling pathways involving Flt3 and CDK, which impact disease progression in acute leukemias. Flt3 mutations are the most frequent genetic alterations reported in acute myeloid leukemia (AML) patients and are associated with a poor prognosis. In addition, over-expression of wild type Flt3 has been found in acute lymphoblastic leukemia (ALL) patients. Cyclin-dependent kinases or CDKs play important roles in cell cycle control. By inhibiting both Flt3 and CDK kinases, SB1317 is uniquely positioned as a "first-in-class" compound to treat relapsed and refractory acute leukemias. SB1317 has already entered preclinical development.

"The ability to maintain long-term control in AML and ALL remains one of the most significant unmet medical needs in the adult leukemia market. SB1317 has been designed with this in mind, and we believe it has the potential to become a first of its kind Flt3 inhibitor to specifically target this group of patients," said Dr. Jan-Anders Karlsson, CEO of S*BIO, "With its ideal profile for treating relapsed and refractory AML and ALL, SB1317 provides an opportunity for S*BIO to expand its portfolio of new targeted therapies for hematological disorders."

Approximately 300,000 new cases of leukemia are diagnosed worldwide each year, and there are about 36,000 new cases of acute leukemia in the seven major pharmaceutical markets*. Acute leukemia is characterized by rapid growth and accumulation of immature blood cells in the bone marrow. This results in fewer normal blood cells. Relapse rates following conventional leukemia treatments remain high and limited treatment options exist for patients who relapse after standard
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
2. Rohm and Haas Expands in India
3. US Med-Equip Expands Corporate Support Center
4. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
5. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
6. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
7. Specialty Blades, Inc. Expands Management Team With New VP Engineering
8. CRH Medical expands Las Vegas operations
9. ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
10. Bipartisan Bill Expands Health Care Access for Small Businesses
11. ABR-Affinity BioReagents Expands 100% Quality Guarantee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... The "North American ... Market by Angioplasty Balloon (Plain/Old, Cutting), ... IVC Filter (Retrievable), Endovascular Stent Graft ... studies the major market drivers, restraints, ... Canada. , Browse 108 market data ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Tylenol ... continue to move forward in the federal multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... Judge Lawrence F. Stengel has ordered the deposition ... Judge Stengel found that the witness’s testimony concerning ...
(Date:7/12/2014)... ON Canada (PRWEB) July 12, 2014 Sean Francis, ... for throwing out special challenges to his clients. He’s also known ... Club. He recently found a way to combine the two and ... has raised $2,000 for the Boys and Girls Club. , The ... Program, which started on June 23rd. Francis sent out emails and ...
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 For those ... are bodies can readily absorb the nutrients in food. The ... particles that are small enough to be absorbed by human ... team, a lack of enzymes in regular food is the ... a product that was started by Michelle DelPresto, a mother ...
(Date:7/12/2014)... Utah (PRWEB) July 12, 2014 Utah ... types of startups, with awards being bestowed to companies ... spotlighted Utah’s outstanding entrepreneur community with recognition for new ... sustainable model with incoming revenue. , 25 Under 5 ... the state that are under 5 years old. Award ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
... A nontoxic nanoparticle developed by Penn State researchers is ... both therapeutic drugs and the fluorescent dyes that can ... of Nano Letters , an interdisciplinary group of ... calcium phosphate particles ranging in size from 20 to ...
... late adulthood, the number of patients with Alzheimer,s disease (AD) ... , A team of national researchers, led by Emory ... cognitive impairment (MCI) often the earliest stage of AD. ... Journal of Alzheimer,s Disease . , The study shows ...
... Author/Therapist Provides New Resource So Families of ,Bad, Children Can ... ORMOND BEACH, Fla., Nov. 18 The holidays ... the stress of the season can foster difficult, even disorderly ... outbursts can destroy a family gathering and leave parents asking, ...
... 18 Women who have decided that they do ... sterilization. Patients who opt for hysteroscopic sterilization need to ... and return to daily activities, also consists of 2 ... (HSG). Both parts of the procedure must be performed ...
... a drug rehab program does not mean they have ... recovery and return to addiction and abuse soon after. ... the patient?" Usually it,s their family and ... counterattack these situations by offering family weekends four times ...
... innovative, cost-effective medical devices, announces immediate availability of an economical ... designed to bring affordable cytology to any size laboratory. ... ... EON) November 18, 2008 -- The NuView System does ...
Cached Medicine News:Health News:Nontoxic nanoparticle can deliver and track drugs 2Health News:Nontoxic nanoparticle can deliver and track drugs 3Health News:New approach to screen individuals for early Alzheimer's disease 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 3Health News:C.A.R.E. Florida Launches Family Weekends to Help on That Long Road to Recovery 2Health News:C.A.R.E. Florida Launches Family Weekends to Help on That Long Road to Recovery 3
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... Surgical Company (Nasdaq: STAA ), the leading ... today announced that the Visian Implantable Collamer® Lens (ICL) ... leading ophthalmologists at meetings prior to and during the ... Surgeons (ESCRS) held in Paris, France from September 4 ...
... Present at the Rodman & Renshaw Annual Global... -- SHENZHEN, China, Sept. 8 /PRNewswire-Asia/ -- ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 2STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 3STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 4STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 5STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 6Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 2Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 3Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 4Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 5Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 6Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: